Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
1. Subjects completing Day 169 (24 weeks) on study medication may be eligible to enter an optional LTE period
2. The LTE period will remain blinded but will no longer have a placebo arm:
* Subjects will remain on their originally assigned treatment arm unless they were on placebo
* Subjects initially randomized to placebo arm will be automatically re-randomized into one of the existing active arms at Day 169 (24 weeks)
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Male or female aged between 18 to 70 (included)
Diagnosed with active systemic lupus erythematosus by a doctor
Disease must be in patient's joints or on the skin at a minimum
Taking other medications is allowed but some are excluded
You may not be if
Diagnosed with active lupus nephritis, multiple sclerosis or rheumatoid arthritis
Diagnosed with active tuberculosis or an ongoing infection with a bacteria or a virus
Clareo Health | Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
